Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag plus lenalidomide in low/intermediate-1 risk del(5q) myelodysplastic syndrome
2015-000362-53Phase 2Active
- Sponsor
- Qol-one
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Eltrombopag + lenalidomide with Placebo + lenalidomide (2 arms). Started Nov 2016; status: active.
02
Drugs
eltrombopaglenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2015-000362-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000362-53.